Objective: To evaluate the effectiveness and safety of omeprazole compared to lansoprazole in Gastroesophageal reflux disease patients (GERD).

Methods: A systematic search of MEDLINE, EMBASE (inception to December 2019) and CENTRAL (January 2011 to December 2019) was conducted to identify the relevant articles. A detailed inclusion-exclusion criterion was developed and implemented to screen the abstracts. Full texts of the selected abstracts were then assessed to establish their inclusion or exclusion in our review. Cochrane risk of bias criterion was used to assess the methodological quality of the included studies. All relevant data were extracted and the results were summarised narratively.

Results: 9 studies met our inclusion-exclusion criteria and were included in this review.  In all three trials reporting on heartburn and regurgitation, both omeprazole and lansoprazole were found to be effective in relieving the symptoms of heartburn and regurgitation; however, there was no evidence that one is better than the other. Five out of six studies reporting on intragastric pH provided the evidence of omeprazole’s superiority over lansoprazole in controlling gastric pH. Omeprazole lowered intragastric pH faster and the results lasted longer compared to lansoprazole. The results were statistically significant.

Conclusion: There is no significant difference in the clinical effectiveness of omeprazole and lansoprazole in relieving symptoms of heartburn and regurgitation. However, omeprazole is more effective in reducing gastric acidity than lansoprazole.


  1. H. Miwa, A. Igarashi, L. Teng, A. Uda, H. Deguchi, and T. Tango, ‘Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease’, J. Gastroenterol., vol. 54, no. 8, pp. 718–729, Aug. 2019, doi: 10.1007/s00535-019-01572-y.
  2. M. MacGill, ‘Everything you need to know about GERD. https://www.medicalnewstoday.com/articles/14085.php. Date accessed: 24th Dec 2019.’, 18-Jan-2018.
  3. M. Clinic, ‘Gastroesophageal reflux Disease (GERD). www.mayoclinic.org. Date accessed: 24th Dec 2019.’ 23-Oct-2019.
  4. Y. Xiao et al., ‘Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis’, Gut, 2019, doi: 10.1136/gutjnl-2019-318365.
  5. E. J. Kim et al., ‘Efficacy and safety of AlbisD compared with omeprazole 20 mg in patients with non-erosive reflux disease: A randomized, open-label, active-controlled, pilot study’, J. Neurogastroenterol. Motil., vol. 25, no. 3, pp. 403–412, 2019, doi: 10.5056/jnm18185.
  6. NHS Inform, ‘Gastro-oesophageal reflux disease (GORD). https://www.nhsinform.scot/illnesses-and-conditions/stomach-liver-and-gastrointestinal-tract/gastro-oesophageal-reflux-disease-gord#causes-of-gord. Date accessed: 24th Dec 2019.’ 30-Sep-2019.
  7. WebMD, ‘Gastroesophageal Reflux Disease (GERD). https://www.webmd.com/heartburn-gerd/guide/reflux-disease-gerd-1#1. Date accessed: 24th Dec 2019.’ .
  8. K. Haruma, Y. Kinoshita, S. Sakamoto, K. Sanada, S. Hiroi, and H. Miwa, ‘Lifestyle factors and efficacy of lifestyle interventions in gastroesophageal reflux disease patients with functional dyspepsia: Primary care perspectives from the LEGEND study’, Intern. Med., vol. 54, no. 7, pp. 695–701, Apr. 2015, doi: 10.2169/internalmedicine.54.3056.
  9. Wikipedia contributors, ‘Proton-Pump Inhibitor. Wikipedia. https://en.wikipedia.org/w/index.php?title=Proton-pump_inhibitor&oldid=935218418. Date accessed: 16th Dec 2019.’ 16-Dec-2019.
  10. WHO, ‘Organization, World Health (2019). “World Health Organization model list of essential medicines: 21st list 2019”. WHO Model List of Essential Medicines, https://en.wikipedia.org/w/index.php?title=WHO_Model_List_of_Essential_Medicines&oldid=93452205. Date accessed: 16th Dec 2019.’.
  11. J. Patrick Waring, ‘Proton Pump Inhibitors (PPIs). https://www.aboutgerd.org/medications/proton-pump-inhibitors-ppis.html. Date accessed: 24th Dec 2019.’
  12. Moher D, Liberati A, Tetzlaff J, Altman DG, ‘Journal of Clinical Epidemiology Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. J Clin Epidemiol 2009; doi:10.1016/j.jclinepi.2009.06.005’, J. Clin. Epidemiol.
  13. Mourad Ouzzani, Hossam Hammady, Zbys Fedorowicz, and Ahmed Elmagarmid., ‘Rayyan — a web and mobile app for systematic reviews. Systematic Reviews (2016) 5:210’, doi: 10.1186/s13643-016-0384-4.
  14. Higgins JPT, Green S (editors)., Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. .
  15. P. O. Katz, J. G. Hatlebakk, and D. O. Castell, ‘Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole’, Aliment. Pharmacol. Ther., vol. 14, no. 6, pp. 709–14, Jun. 2000.
  16. P. B. Miner Jr, L. A. McKean, R. D. Gibb, G. N. Erasala, D. L. Ramsey, and J. W. McRorie, ‘Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors’, Aliment. Pharmacol. Ther., vol. 31, no. 8, pp. 846–51, Apr. 2010, doi: 10.1111/j.1365-2036.2010.04258.x.
  17. Y. Funaki et al., ‘Comparison of the effect of a single dose of omeprazole or lansoprazole on intragastric pH in Japanese participants: A two-way crossover study’, J. Chin. Med. Assoc., vol. 76, no. 3, pp. 131–134, Mar. 2013, doi: 10.1016/j.jcma.2012.11.006.
  18. E. Vivian, A. Morreale, E. Boyce, K. Lowry, O. Ereso, and P. Hlavin, ‘Efficacy and cost effectiveness of lansoprazole versus omeprazole in maintenance treatment of symptomatic gastroesophageal reflux disease’, Am. J. Manag. Care, vol. 5, no. 7, pp. 881–886, 1999.
  19. P. O. Katz, S. Xue, and D. O. Castell, ‘Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg’, Aliment. Pharmacol. Ther., vol. 15, no. 5, pp. 647–52, May 2001.
  20. I. Janczewska, M. Sagar, S. Sjöstedt, B. Hammarlund, M. Iwarzon, and R. Seensalu, ‘Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease’, Scand. J. Gastroenterol., vol. 33, no. 12, pp. 1239–43, Dec. 1998.
  21. C. W. Howden, E. D. Ballard, F. K. Koch, T. C. Gautille, and R. G. Bagin, ‘Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD’, J. Clin. Gastroenterol., vol. 43, no. 4, pp. 323–6, Apr. 2009, doi: 10.1097/MCG.0b013e31818a386e.
  22. R. Fass et al., ‘Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study’, Aliment. Pharmacol. Ther., vol. 14, no. 12, pp. 1595–603, Dec. 2000.
  23. N. Arezoomandi and P. Adibi, ‘Comparison of the effect of omeprazole, pantoprazole, esomeprazole, and lansoprazole on the reduction of symptoms in patients with gastroesophageal reflux disease’, J. Isfahan Med. Sch., vol. 36, no. 507, p. 1498‐1504, 2019, doi: 10.22122/jims.v36i507.10815.
  24. İ. Hatemi and S. N. Esatoğlu, ‘What is the long term acid inhibitor treatment in gastroesophageal reflux disease? What are the potential problems related to long term acid inhibitor treatment in gastroesophageal reflux disease? How should these cases be followed?’, Turk. J. Gastroenterol., vol. 28, pp. S57–S60, 2017, doi: 10.5152/tjg.2017.15.
  25. W. Tarsin, I. Alshamli, E. Alabbasi, E. Naas, and M. Soussi, ‘The relationship between acidic & non acidic gastro esophageal reflux disease (GERD) and asthma’, Eur. Respir. J., vol. 38, Sep. 2011.
  26. M. Abbasinazari et al., ‘Effect of a combination of omeprazole plus sustained release baclofen versus omeprazole alone on symptoms of patients with Gastroesophageal Reflux Disease (GERD)’, Iran. J. Pharm. Res., vol. 13, no. 4, pp. 1221–1226, Sep. 2014.
  27. H. Joshaghani et al., ‘Effects of omeprazole consumption on serum levels of trace elements’, J. Trace Elem. Med. Biol., vol. 26, no. 4, pp. 234–237, Oct. 2012, doi: 10.1016/j.jtemb.2012.02.002.
  28. P. O. Katz et al., ‘Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms’, Aliment. Pharmacol. Ther., vol. 25, no. 2, pp. 197–205, Jan. 2007.

Comments & Peer Review

Must Read